Linked Life Data

7654826

Source:http://linkedlifedata.com/resource/pubmed/id/7654826

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1995-10-5
pubmed:abstractText
The identification and development of new agents and innovative treatment approaches remain a priority. The prognosis for patients with recurrent or metastatic head and neck cancer remains poor; thus participation in trials of promising investigational agents is an important option for these individuals. For patients with locally advanced tumors, combined modality treatment is undergoing rapid evolution. The optimal combination and sequence of therapies have yet to be determined. However, available data support an increasing role for chemotherapy especially as part of strategies to preserve organ function and treat unresectable disease.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1040-8746
pubmed:author
pubmed:issnType
Print
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
242-7
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1995
pubmed:articleTitle
Chemotherapy for recurrent disease and combined modality therapies for head and neck cancer.
pubmed:affiliation
Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
pubmed:publicationType
Journal Article, Review